Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid

Journal of Neuroscience Methods

Volumn 167, Issue 2, 2008, Pages 229-236

  Miners, James Scott ^a   Verbeek, Marcel M ^b   Rikkert, Marcel Olde ^b   Kehoe, Patrick Gavin ^a   Love, Seth ^a  

^a Institute of Clinical Neurosciences   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cerebrospinal fluid; Fluorogenic substrate; Immunocapture; Neprilysin; Thiorphan

Indexed keywords

ANTIBODY; MEMBRANE METALLOENDOPEPTIDASE; NEPRILYSIN ANTIBODY; PEPTIDE; THIORPHAN; UNCLASSIFIED DRUG;

ALKALINITY; ARTICLE; BRAIN TISSUE; CEREBROSPINAL FLUID; ENZYME ACTIVITY; ENZYME IMMOBILIZATION; ENZYME ISOLATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; FLUOROMETRY; HIGH THROUGHPUT SCREENING; IMMUNOASSAY; IMMUNOCAPTURE; PRIORITY JOURNAL; REACTION ANALYSIS; TISSUE HOMOGENATE;

BRAIN; BRAIN CHEMISTRY; CEREBROSPINAL FLUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT DYES; FLUOROMETRY; HUMANS; NEPRILYSIN; OLIGONUCLEOTIDES; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; THIORPHAN; TIME FACTORS;

EID: 37049011221     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2007.08.012     Document Type: Article

References (31)

1. Battistini B., Daull P., and Jeng A.Y. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev 23 (2005) 317-330
2. Carson J.A., and Turner A.J. Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases?. J Neurochem 81 (2002) 1-8
3. Carvalho K.M., Boileau G., Camargo A.C., and Juliano L. A highly selective assay for neutral endopeptidase based on the cleavage of a fluorogenic substrate related to Leu-enkephalin. Anal Biochem 237 (1996) 167-173
4. Chersi A., Ferracuti S., Falasca G., Butler R.H., and Fruci D. Assembly and selective "in synthesis" labeling of quenched fluorogenic protease substrates. Anal Biochem 357 (2006) 194-199
5. Di Marco G.S., Quinto B.M., Juliano M., Carmona A.K., Stella R.C., Plavnik F.L., and Casarini D.E. Purification and characterization of a neutral endopeptidase-like enzyme from human urine. J Hypertens 16 (1998) 1971-1978
6. Fahnoe D.C., Knapp J., Johnson G.D., and Ahn K. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH. J Cardiovasc Pharmacol 36 (2000) S22-S25
7. Goudreau N., Guis C., Soleilhac J.M., and Roques B.P. Dns-Gly-(p-NO2)Phe-beta Ala, a specific fluorogenic substrate for neutral endopeptidase 24111. Anal Biochem 219 (1994) 87-95
8. Jeng A.Y., Fujimoto R.A., Chou M., Tan J., and Erion M.D. Suppression of substance P biosynthesis in sensory neurons of dorsal root ganglion by prodrug esters of potent peptidylglycine alpha-amidating monooxygenase inhibitors. J Biol Chem 272 (1997) 14666-14671
9. Johnson G.D., and Ahn K. Development of an internally quenched fluorescent substrate selective for endothelin-converting enzyme-1. Anal Biochem 286 (2000) 112-118
10. Lauer-Fields J.L., Nagase H., and Fields G.B. Development of a solid-phase assay for analysis of matrix metalloproteinase activity. J Biomol Tech 15 (2004) 305-316
11. Loffler B.M. Endothelin-converting enzyme inhibitors: current status and perspectives. J Cardiovasc Pharmacol 35 (2000) S79-S82
12. Miners J.S., Van Helmond Z., Chalmers K., Wilcock G., Love S., and Kehoe P.G. Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65 (2006) 1012-1021
13. Morty R.E., Vadasz I., Bulau P., Dive V., Oliveira V., Seeger W., and Juliano L. Tropolysin, a new oligopeptidase from African trypanosomes. Biochemistry 44 (2005) 14658-14669
14. Mzhavia N., Pan H., Che F.Y., Fricker L.D., and Devi L.A. Characterization of endothelin-converting enzyme-2.Implication for a role in the nonclassical processing of regulatory peptides. J Biol Chem 278 (2003) 14704-14711
15. Ocaranza M.P., Godoy I., Jalil J.E., Varas M., Collantes P., Pinto M., Roman M., Ramirez C., Copaja M., Diaz-Araya G., Castro P., and Lavandero S. Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48 (2006) 572-578
16. Oliveira V., Campos M., Hemerly J.P., Ferro E.S., Camargo A.C., Juliano M.A., and Juliano L. Selective neurotensin-derived internally quenched fluorogenic substrates for neurolysin (EC 3.4. 24. 16): comparison with thimet oligopeptidase (EC 3. 4. 24. 15) and neprilysin (EC 3. 4. 24. 11). Anal Biochem 292 (2001) 257-265
17. Papandreou C.N., Usmani B., Geng Y., Bogenrieder T., Freeman R., Wilk S., Finstad C.L., Reuter V.E., Powell C.T., Scheinberg D., Magill C., Scher H.I., Albino A.P., and Nanus D.M. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4 (1998) 50-57
18. Quaschning T. Vasopeptidase inhibition for blood pressure control: emerging experience. Curr Pharm Des 11 (2005) 3293-3299
19. Quinto B.M., Juliano L., Juliano M., Carmona A.K., Stella R.C., and Casarini D.E. Characterization of a kinin inactivating serine endopeptidase H2 (kininase) from human urine using fluorogenic substrates. Immunopharmacology 45 (1999) 223-228
20. Quinto B.M., Juliano M.A., Hirata I., Carmona A.K., Juliano L., and Casarini D.E. Characterization of a prolyl endopeptidase (kininase) from human urine using fluorogenic quenched substrates. Int J Biochem Cell Biol 32 (2000) 1161-1172
21. Quinto B.M., Juliano M.A., Hirata I., Carmona A.K., Juliano L., and Casarini D.E. Specificity comparison of a serine endopeptidase (SH1) and a serine thiol endopeptidase (STH2) purified from human urine. Int J Biochem Cell Biol 36 (2004) 1933-1944
22. Sigman J.A., Patwa T.H., Tablante A.V., Joseph C.D., Glucksman M.J., and Wolfson A.J. Flexibility in substrate recognition by thimet oligopeptidase as revealed by denaturation studies. Biochem J 388 (2005) 255-261
23. Sumitomo M., Shen R., and Nanus D.M. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 1751 (2005) 52-59
24. Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 63 (2003) 2185-2202
25. Takaki Y., Iwata N., Tsubuki S., Taniguchi S., Toyoshima S., Lu B., Gerard N.P., Gerard C., Lee H.J., Shirotani K., and Saido T.C. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J Biochem 128 (2000) 897-902
26. Turner A.J. Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. Biochem Soc Trans 31 (2003) 723-727
27. Turner A.J., Brown C.D., Carson J.A., and Barnes K. The neprilysin family in health and disease. Adv Exp Med Biol 477 (2000) 229-240
28. Turner A.J., Isaac R.E., and Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 23 (2001) 261-269
29. Turner A.J., and Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 11 (1997) 355-364
30. Vardy E.R., Catto A.J., and Hooper N.M. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. Trends Mol Med 11 (2005) 464-472
31. Wang D.S., Lipton R.B., Katz M.J., Davies P., Buschke H., Kuslansky G., Verghese J., Younkin S.G., Eckman C., and Dickson D.W. Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 64 (2005) 378-385